Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Boston Partners

Key Points

• Boston Partners has reduced its stake in Catalyst Pharmaceuticals by 1.3%, now holding approximately 1.05% of the company valued at $30.6 million after selling 16,543 shares.
• Despite Boston Partners' reduction, several institutional investors, including GAMMA Investing LLC and Summit Investment Advisors Inc., have increased their stakes, highlighting ongoing interest in the biopharmaceutical firm.
• The stock price of Catalyst Pharmaceuticals is currently $20.07 with analysts rating it as "Buy" on average, indicating positive market sentiment despite a recent slight decline of 0.6% in stock value.

Boston Partners lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,275,325 shares of the biopharmaceutical company's stock after selling 16,543 shares during the quarter. Boston Partners owned approximately 1.05% of Catalyst Pharmaceuticals worth $30,628,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in CPRX. LPL Financial LLC raised its stake in shares of Catalyst Pharmaceuticals by 38.0% during the 4th quarter. LPL Financial LLC now owns 57,983 shares of the biopharmaceutical company's stock worth $1,210,000 after buying an additional 15,961 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Catalyst Pharmaceuticals by 162.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 64,395 shares of the biopharmaceutical company's stock worth $1,344,000 after purchasing an additional 39,836 shares in the last quarter. Bank of Montreal Can increased its position in Catalyst Pharmaceuticals by 6.2% during the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 875 shares in the last quarter. Legal & General Group Plc increased its position in Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Legal & General Group Plc now owns 344,623 shares of the biopharmaceutical company's stock worth $7,192,000 after purchasing an additional 9,741 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $6,887,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Up 0.3%

CPRX traded up $0.0650 during midday trading on Wednesday, hitting $20.3150. The company's stock had a trading volume of 101,239 shares, compared to its average volume of 1,311,401. The firm has a market cap of $2.49 billion, a P/E ratio of 12.32, a PEG ratio of 0.82 and a beta of 0.70. The firm has a 50-day moving average price of $21.51 and a two-hundred day moving average price of $22.65. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Wall Street Zen cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Two analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $33.20.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider owned 41,081 shares in the company, valued at $1,085,360.02. The trade was a 3.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.40% of the stock is owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.